参考文献/References:
[1] DONG X,FU J,YIN X,et al.Emodin:a review of its pharmacology,toxicity and pharmacokinetics[J].Phytother Res,2016,30(8):1207-1218. [2] 薛丽,唐坚,褚永权,等.大黄素对胰腺癌裸鼠皮下移植瘤抑癌基因去甲基化作用[J].医学研究杂志,2018,47(1):74-78. [3] 刘原兴,沈乃营,刘昌,等.大黄素在小鼠皮肤移植中的免疫抑制作用的实验研究[J].第四军医大学学报,2009,30(4):301-304. [4] TONG H,CHEN K,CHEN H,et al.Emodin prolongs recipient survival time after orthotopic liver transplantation in rats by polarizing the Th1/Th2 paradigm to Th2[J].Anat Rec(Hoboken),2011,294(3):445-452. [5] QIU F,LIU H,LIANG C L,et al.A new immunosuppressive molecule emodin induces both CD4+,FoxP3+ and CD8+,CD122+regulatory T cells and suppresses murine allograft rejection[J].Front Immunol,2017,8(11):1519-1525. [6] 蔡春晓,马春梅,孟立正,等.小鼠异种皮肤移植模型的建立及对免疫抑制药物的药效评价[J].中国药理学通报,2016,32(11):1613-1619. [7] 孟珂伟,宋占文,周先亭,等.大黄素对大鼠原位肝移植术后急性排斥反应的干预[J].中国组织工程研究与临床康复,2007,11(47):9427-9430. [8] 荆河,林胜璋,杨潇,等.大黄素和环孢素A在抗大鼠肝移植排斥反应中的协同作用[J].中国中西医结合杂志,2008,28(7):614-616. [9] LOPEZ-HOYOS M,SAN SEGUNDO D,BRUNET M.Regulatory T cells as biomarkers for rejection and immunosuppression tailoring in solid organ transplantation[J].Ther Drug Monit,2016,38(Suppl 1):36-42. [10] WANG M M,YANG Y L,SUN J J,et al.Induction of immune tolerance and altered cytokine expression in skin transplantation recipients[J].Kaohsiung J Med Sci,2018,34(6):330-334. [11] KE N,SU A,HUANG W,et al.Regulating the expression of CD80/CD86 on dendritic cells to induce immune tolerance after xeno-islet transplantation[J].Immunobiology,2016,221(7):803-812. [12] LI B,TIAN L,DIAO Y,et al.Exogenous IL-10 induces corneal transplantation immune tolerance by a mechanism associated with the altered Th1/Th2 cytokine ratio and the increased expression of TGF-β[J].Mol Med Rep,2014,9(6):2245-2250. [13] 林文琴,杨潇,荆河,等.大黄素对大鼠肝移植排斥反应相关细胞因子的影响[J].中草药,2008,39(12):1853-1855. [14] 荆河,林胜璋,杨潇.大黄素对大鼠原位肝移植急性排斥反应中TNF-α,IL-10水平的影响[J].中国中药杂志,2009,34(11):1435-1438. [15] 袁劲,吴轲,陈忠华.体外分化的CD4+,CD25+调节性T细胞可减轻小鼠皮肤移植急性排斥反应[J].华中科技大学学报(医学版),2010,39(6):733-737. [16] 蒋力,刘垚,张珂,等.大黄素对大鼠肝移植后CD4+,CD25+调节性T细胞的影响[J].中华实验和临床感染病杂志(电子版),2010,4(3):271-277.